Evidence map›Paper›PMID 33999309›Full record

ReviewScience China. Life sciences2021

AFAP1-AS1: a rising star among oncogenic long non-coding RNAs.

Fang Xiong, Kunjie Zhu, Su Deng, Hongbin Huang, Liting Yang, Zhaojian Gong, Lei Shi, Yi He, Yanyan Tang, Qianjin Liao and 8 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Science China. Life sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. The Emerging Role of METTL3 in Lung Diseases.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Progress on long non-coding RNAs in calcific aortic valve disease.Frontiers in cardiovascular medicine · 2025
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. RNA modifications in cancer.British journal of cancer · 2023
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. The role of alternative splicing in human cancer progression.American journal of cancer research · 2021
    Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Fang XiongScience and Technology on Information System Engineering Laboratory, National University of Defense Technology, Changsha, 410000, China.
Kunjie ZhuHunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Su DengScience and Technology on Information System Engineering Laboratory, National University of Defense Technology, Changsha, 410000, China.
Hongbin HuangScience and Technology on Information System Engineering Laboratory, National University of Defense Technology, Changsha, 410000, China.
Liting YangDepartment of Periodontology, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, 410078, China.
Zhaojian GongDepartment of Oral and Maxillofacial Surgery, The Second Xiangya Hospital Central South University, Changsha, 410011, China.
Lei ShiDepartment of Oral and Maxillofacial Surgery, The Second Xiangya Hospital Central South University, Changsha, 410011, China.
Yi HeHunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Yanyan TangHunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Qianjin LiaoHunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Jianjun YuHunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Xiaoling LiNHC Key Laboratory of Carcinogenesis and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education of China, Cancer Research Institute, Central South University, Changsha, 410078, China.
Yong LiDepartment of Medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
Guiyuan LiNHC Key Laboratory of Carcinogenesis and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education of China, Cancer Research Institute, Central South University, Changsha, 410078, China.
Zhaoyang ZengNHC Key Laboratory of Carcinogenesis and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education of China, Cancer Research Institute, Central South University, Changsha, 410078, China.
Wei XiongNHC Key Laboratory of Carcinogenesis and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education of China, Cancer Research Institute, Central South University, Changsha, 410078, China.
Shanshan ZhangDepartment of Periodontology, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, 410078, China. zhangshanshan@csu.edu.cn.
Can GuoNHC Key Laboratory of Carcinogenesis and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education of China, Cancer Research Institute, Central South University, Changsha, 410078, China. guocde@csu.edu.cn.
Central South University · CNHunan Cancer Hospital · CNNational University of Defense Technology · CNBaylor College of Medicine · USSecond Xiangya Hospital of Central South University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) have become a hotspot in biomedical research. This interest reflects their extensive involvement in the regulation of the expression of other genes, and their influence on the occurrence and development of a variety of human diseases. Actin filament associated protein 1-Antisense RNA 1(AFAP1-AS1) is a recently discovered oncogenic lncRNA. It is highly expressed in a variety of solid tumors, and regulates the expression of downstream genes and signaling pathways through adsorption and competing microRNAs, or by the direct binding to other proteins. Ultimately, AFAP1-AS1 promotes proliferation, chemotherapy resistance, and resistance to apoptosis, maintains stemness, and enhances invasion and migration of tumor cells. This paper summarizes the research concerning AFAP1-AS1 in malignant tumors, including the clinical application prospects of AFAP1-AS1 as a potential molecular marker and therapeutic target of malignant tumors. We also discuss the limitations in the knowledge of AFAP1-AS1 and directions of further research. AFAP1-AS1 is expected to provide an example for studies of other lncRNA molecules.

Indexed as

Biomarkers, TumorCarcinogenesisGene Expression Regulation, NeoplasticHumansMicrofilament ProteinsMicroRNAsNeoplasmsRNA, AntisenseRNA-Binding ProteinsRNA, Long NoncodingUp-RegulationAFAP1 protein, humanBiomarkers, TumorMicrofilament ProteinsMicroRNAsRNA, AntisenseRNA-Binding ProteinsRNA, Long NoncodingAFAP1-AS1anti-cancer drugimmunotherapymetastasisPD-1proliferation

Identifiers

PMID33999309
OpenAlexW3160234945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.